Neuland Laboratories Appoints Saharsh Davuluri as New CEO & MD

• Neuland Laboratories Limited announced Saharsh Davuluri as its new CEO and MD, effective immediately.
• Saharsh Davuluri replaces Sucheth Davuluri, who will now serve as Executive Vice Chairman.
• Saharsh, with 18 years at Neuland, will lead the next phase of CDMO business expansion.
• The company has tripled its contract service revenue in the last three years, driven by expertise in complex APIs and peptides.
• Neuland plans a four-phase peptide capacity expansion and aims to be a top-5 API-based CDMO globally.